期刊文献+

放射性粒子植入联合酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的远期疗效分析 被引量:8

Long-term Efficacy of Radioactive Seed Implantation Combined with Tyrosine Kinase Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer
在线阅读 下载PDF
导出
摘要 目的探究放射性粒子植入联合酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的远期疗效。方法选取晚期非小细胞肺癌患者(突变阳性且为ⅢB~Ⅳ期的不可通过手术方法切除)52例作为该研究的对象,分为观察组和对照组,观察组患者26例,行放射性粒子植入联合酪氨酸激酶抑制剂治疗,对照组26例,选择单药酪氨酸激酶抑制剂治疗,治疗结束后对不同组患者的临床治疗率、不良反应以及生存率进行比较和分析。结果观察组局部控制率为92.31%,对照组局部控制率为65.38%,组间差异显著,具有统计学的意义(P<0.05);两组患者的有效率组间比较无显著差异,无统计学意义(P>0.05);两组患者不良反应发生率比较无显著差异,无统计学意义(P<0.05),观察组患者出现1例Ⅲ度白细胞脱落,治疗后恢复正常,两组患者均无出现对其他脏器的功能损害;观察组患者的1年生存率为80.76%,对照组患者的1年生存率为61.54%,组间差异显著,具有统计学意义(P<0.05);观察组患者2年生存率为65.38%,对照组患者的2年生存率为38.46%,组间差异显著,具有统计学意义(P<0.05);观察组的无进展生存时间以及中位生存时间也长于对照组(P<0.05)。结论酪氨酸激酶抑制剂联合植入放射性粒子治疗晚期的非小细胞肺癌疗效优于单药,是一种有效性高、安全性好的治疗方法,值得推广。 Objective To explore the long-term effect of radioactive seed implantation combined with tyrosinc kiuase inhibitor in the treatment of advanced non-small cell lung cancer. Methods 52 cases of advanced non-small cell lung cancer pa- tients( mutation positive and for stage ⅢB -Ⅳ cannot be surgically removed) were selected as research objects, they were divid- ed into observation group and the control group, the observation group( n = 26) were given radioactive particles implantatian com- bined with tyrosine kinase inhibitor treatment ,the control group( 26 cases) were given choice of siugle drug of tyresine kinase in- hibitor treatment, after the end of treatment, the clinical treatment rates, adverse reactions and survival rates of different groups were compared and analyzed. Results The local control rate of the observation group was 92. 31% ,the local control rate of the control group was 65.38% , the difference between the 2 groups was significant, there had statistical significance( P 〈 0.05 ) ;The difference of the efficiency between the 2 groups was not significant, there had no statistical significance ( P 〉 0. 05 ) ; The differ- ence of the incidences of adverse reactions between the 2 groups was not significant, there had no statistical significance ( P 〈 0.05 ), the observation group had white blood cell shedding, after treatment returned to normal, the two groups had no functional damage to other organs ; 1 -year survival rate of the observation group was 80.76%, 1 -year survival rate of the control group was 61.54% ,the difference between the 2 groups was significant,there had statistical significance( P 〈 0.05 ) ;2-year smwival rate of the observation group was 65.38% ,2-year survival rate of the control group was 38.46% ,the ditfercnce between the 2 groups was significant, there had statistical significance( P 〈 0.05). The progression free survival time and median survival time of the obser- vation group were longer than those of the control group ( P 〈 0.05 ). Conclusion The curative effect of radioactive seed implan- tation combined with tyrosine kinase inhibitor in the treatment of advanced non small cell lung cancer is better than that of siagle drug, it is an effective and safe treatment methods, so is worthy of promotion.
出处 《实用癌症杂志》 2017年第8期1294-1297,共4页 The Practical Journal of Cancer
基金 陕西省国际合作项目资助号(编号:2015KW-038)
关键词 放射粒子 酪氨酸激酶抑制剂 非小细胞肺癌 Radioactive particles Tyrosine kinase inhibitors Non-small cell lung cancer
  • 相关文献

参考文献14

二级参考文献243

  • 1吕蕾,缪建华,陈暑波,张迦维.吉非替尼联合艾迪治疗老年非小细胞肺癌的临床研究[J].齐齐哈尔医学院学报,2006,27(17):2057-2059. 被引量:16
  • 2邓俭.华蟾素联合吉非替尼治疗晚期非小细胞肺癌临床观察[J].中国现代药物应用,2007,1(11):29-30. 被引量:14
  • 3王孟昭,张晓彤,张新勇,张力,钟巍,徐丽艳,李龙芸.厄罗替尼单药治疗晚期非小细胞肺癌的疗效和安全性分析[J].中国医学科学院学报,2010,32(2):151-156. 被引量:7
  • 4周晓蓉,徐士玲,刘建红,顾慧.复方锡类散液保留灌肠治疗化疗引起的严重腹泻[J].临床肿瘤学杂志,2005,10(5):540-541. 被引量:13
  • 5尤建良.晚期肺癌靶向治疗时中医药的切入[J].辽宁中医杂志,2006,33(10):1227-1229. 被引量:23
  • 6陈竺,主编.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008:15.
  • 7FUKUOKA M, WU YL, THONGPRASERT S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, ran- domized, open-label, first-line study of gefitinib versus carbopla- tin/paclitaxel in clinically selected patients with advanced non- small-cell lung cancer in Asia (IPASS) [ J ]. J Clin Oncol, 2011,29 (21) :2866 - 2874.
  • 8HAN JY, PARK K, KIM SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never- smokers with adenocarcinoma of the lung [ J ]. J Clin Oncol, 2012,30(10) :1122 - 1128.
  • 9MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib ver- sus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor recep- tor (WJTOG3405): an open label, randomised phase 3 trial [J]. Lancet Oncol, 2010,11(2) :121-128.
  • 10ZHOU C, WU YL, CHEN G,et al. Erlotinib versus chemothera- py as first-line treatment for patients with advanced EGFR muta- tion-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802) : a muhicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol, 2011,12(8) :735 -742.

共引文献88

同被引文献83

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部